臨床整形外科50巻3号

2015年03月発行

誌上シンポジウム 骨軟部腫瘍における画像評価最前線

悪性骨軟部腫瘍に対するFDG-PETの役割

著者： 星学¹ 大戎直人¹ 家口尚¹ 中村博亮¹

所属機関： ¹大阪市立大学大学院医学研究科整形外科教室

ページ範囲：P.237 - P.242

　悪性骨軟部腫瘍に対し施行したFDG-PETによるSUVmaxの意義を検討した．骨腫瘍では骨巨細胞腫のSUVmaxは，骨肉腫，軟骨肉腫よりも高値を示した．軟部腫瘍では，横紋筋肉腫，悪性末梢神経鞘腫瘍，類上皮肉腫，悪性線維性組織球腫が高値を示していた．脂肪肉腫では，多形型，脱分化型が粘液型，高分化型よりも高値を示しており，悪性度を反映している可能性があった．現段階ではFDG-PETは骨軟部腫瘍では良性，悪性の鑑別には応用できないとされている．今後，各組織型に焦点を絞って悪性度評価，転移の有無の診断，治療効果，再発評価を解析していく必要がある．

参考文献

1) Aoki J, Watanabe H, Shinozaki T, et al:FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 32:133-138, 2003

2) Caldarella C, Salsano M, Isgrò MA, et al:The Role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the Response to Neoadjuvant Treatment in patients with osteosarcoma. Int J Mol Imaging 2012:870301, 2012

3) Charest M, Hickeson M, Lisbona R, et al:FDG PET/CT imaging in primary osseous and soft tissue sarcomas:a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36:1944-1951, 2009

4) Cistaro A, Lopci E, Gastaldo L, et al:The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer 59:1206-1210, 2012

5) Dehdashti F, Siegel BA, Griffeth LK, et al:Benign versus malignant intraosseous lesions:discrimination by means of PET with 2-［F-18］ fluoro-2-deoxy-D-glucose. Radiology200:243-247, 1996

6) Feldman F, van Heertum R, Manos C:18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32:201-208, 2003

7) Fortes DL, Allen MS, Lowe VJ, et al:The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Eur J Cardiothorac Surg 34:1223-1227, 2008

8) Gould MK, Maclean CC, Kuschner WG, et al:Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions:a meta-analysis. JAMA 285:914-924, 2001

9) Hamada K, Ueda T, Higuchi I, et al:Peripheral nerve schwannoma:two cases exhibiting increased FDG uptake in early and delayed PET imaging. Skeletal Radiol 34:52-57, 2005

10) Kern KA, Brunetti A, Norton JA, et al:Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29:181-186, 1988

F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 40:728-36, 2013

12) Quartuccio N, Treglia G, Salsano M, et al:The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 47:97-102, 2013

13) Schwab JH, Healey JH:FDG-PET lacks sufficient sensitivity to detect myxoid liposarcoma spinal metastases detected by MRI. Sarcoma 36785, 2007

14) Watanabe H, Shinozaki T, Yanagawa T, et al:Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 82:760-767, 2000